Oxford vaccine preparation technology 5
On November 23, pharmaceutical company AstraZeneca and Oxford University announced that the ChAdOx vaccine is 90% effective depending on the dose.
The vaccine’s protection level ranges from 62-90%, depending on the dose.
The trial used a control group and a placebo, the meningitis vaccine.
The Oxford vaccine is prepared using vector technology, using a harmless cold virus (adenovirus) from chimpanzees, cultured in the laboratory.
To date, Covid-19 vaccines developed based on vector technology include Sputnik-V by Gamaleya Institute (Russia), Adenovirus 26 by Johnson & Johnson (USA) and Ad5 by CanSino (China).
Scientist from the Jenner Institute, Oxford University is researching the ChAdOx vaccine.
Currently, no vaccine from a viral vector has been officially approved, including Sputnik, which was approved for emergency use by Russia.
When Covid-19 appeared, the team of scientists at Oxford University’s Jenner Institute had a good start.
In April, Oxford became a development and manufacturing partner with AstraZeneca.
In May, the US Department of Health and Human Services (HHS) committed $1.2 billion to fund the development and production of the Oxford/AstraZeneca vaccine.
Typically, vaccines need to be stored in the `cold chain` to keep the active ingredient intact and stable when it reaches the patient.
Oxford vaccine can be stored long-term at 2-8 degrees Celsius, the temperature of a regular refrigerator.
Public health experts warn of the challenge of building distribution networks around the world, especially at a time when budgets are tightening in many places.
